NO20052265L - Etylendicystein (EC)-medikament konjugater og fremgangsmater for vevsspesifik sykdomsbilleddannelse - Google Patents
Etylendicystein (EC)-medikament konjugater og fremgangsmater for vevsspesifik sykdomsbilleddannelseInfo
- Publication number
- NO20052265L NO20052265L NO20052265A NO20052265A NO20052265L NO 20052265 L NO20052265 L NO 20052265L NO 20052265 A NO20052265 A NO 20052265A NO 20052265 A NO20052265 A NO 20052265A NO 20052265 L NO20052265 L NO 20052265L
- Authority
- NO
- Norway
- Prior art keywords
- monoclonal antibody
- methods
- ligand
- ethylenedicycin
- tissue
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 238000003384 imaging method Methods 0.000 title 1
- 239000003446 ligand Substances 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 abstract 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 abstract 1
- 102000012936 Angiostatins Human genes 0.000 abstract 1
- 108010079709 Angiostatins Proteins 0.000 abstract 1
- 102000009151 Luteinizing Hormone Human genes 0.000 abstract 1
- 108010073521 Luteinizing Hormone Proteins 0.000 abstract 1
- MXNRLFUSFKVQSK-QMMMGPOBSA-O N(6),N(6),N(6)-trimethyl-L-lysine Chemical compound C[N+](C)(C)CCCC[C@H]([NH3+])C([O-])=O MXNRLFUSFKVQSK-QMMMGPOBSA-O 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 abstract 1
- 229960001097 amifostine Drugs 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 abstract 1
- 230000022131 cell cycle Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002372 labelling Methods 0.000 abstract 1
- 229940040129 luteinizing hormone Drugs 0.000 abstract 1
- 229960003581 pyridoxal Drugs 0.000 abstract 1
- 235000008164 pyridoxal Nutrition 0.000 abstract 1
- 239000011674 pyridoxal Substances 0.000 abstract 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 abstract 1
- 229960003433 thalidomide Drugs 0.000 abstract 1
- 230000005747 tumor angiogenesis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0487—Metallocenes, i.e. complexes based on a radioactive metal complexed by two cyclopentadienyl anions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/081—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the protein being an albumin, e.g. human serum albumin [HSA], bovine serum albumin [BSA], ovalbumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42449302P | 2002-11-07 | 2002-11-07 | |
| PCT/US2003/036078 WO2004044227A2 (en) | 2002-11-07 | 2003-11-07 | Ethylenedicysteine (ec)-drug conjugates, compositions and methods for tissue specific disease imaging |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052265D0 NO20052265D0 (no) | 2005-05-10 |
| NO20052265L true NO20052265L (no) | 2005-08-03 |
Family
ID=32312817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052265A NO20052265L (no) | 2002-11-07 | 2005-05-10 | Etylendicystein (EC)-medikament konjugater og fremgangsmater for vevsspesifik sykdomsbilleddannelse |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20040166058A1 (zh) |
| EP (2) | EP1562641A4 (zh) |
| JP (1) | JP2006515835A (zh) |
| KR (1) | KR101086690B1 (zh) |
| CN (2) | CN101985443A (zh) |
| AU (2) | AU2003297261B2 (zh) |
| BR (1) | BR0316046A (zh) |
| CA (1) | CA2505537A1 (zh) |
| IL (1) | IL168376A (zh) |
| NO (1) | NO20052265L (zh) |
| PL (1) | PL377107A1 (zh) |
| WO (1) | WO2004044227A2 (zh) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002087424A2 (en) | 2001-05-02 | 2002-11-07 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
| US8043603B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| US8043602B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| CA2527196C (en) | 2003-05-30 | 2012-10-16 | Purdue Research Foundation | Diagnostic method for atherosclerosis |
| US7601341B2 (en) * | 2003-06-05 | 2009-10-13 | Research Development Foundation | Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis |
| WO2005063786A2 (en) * | 2003-12-22 | 2005-07-14 | F.Hoffman-La Roche Ag | Process for fluorocytidine derivatives |
| WO2005087275A2 (en) * | 2004-03-11 | 2005-09-22 | Board Of Regents, The University Of Texas System | Metal radiolabeled pet imaging agents |
| CA2592302C (en) * | 2004-12-23 | 2013-10-29 | Purdue Research Foundation | Positron emission tomography imaging method |
| AU2006204045B2 (en) * | 2005-01-05 | 2010-10-14 | Board Of Regents, The University Of Texas System | Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications |
| US20070025957A1 (en) * | 2005-04-29 | 2007-02-01 | Rosenblum Michael G | Vascular targeting of ocular neovascularization |
| JP5175723B2 (ja) | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
| EP1940473A2 (en) | 2005-09-23 | 2008-07-09 | Purdue Research Foundation | Multiphoton in vivo flow cytometry method and device |
| US10925977B2 (en) * | 2006-10-05 | 2021-02-23 | Ceil>Point, LLC | Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications |
| EP2087337A4 (en) | 2006-11-03 | 2010-09-08 | Purdue Research Foundation | METHOD AND DEVICE FOR EX-VIVO FLOW CYTOMETRY |
| WO2008064040A2 (en) * | 2006-11-22 | 2008-05-29 | The Board Of Regents Of The University Of Texas System | Methods and compositions using chelator-antibody conjugates |
| AU2008213702B2 (en) | 2007-02-07 | 2014-04-24 | Purdue Research Foundation | Positron emission tomography imaging method |
| US8961926B2 (en) | 2007-05-25 | 2015-02-24 | Purdue Research Foundation | Method of imaging localized infections |
| GB0804406D0 (en) * | 2008-03-10 | 2008-04-16 | Univ Zuerich | Metal complexes |
| EP2268320A4 (en) * | 2008-03-24 | 2014-10-01 | Univ Texas | IMAGING THERAPY OF MYOKARD DISEASE: COMPOSITION, MANUFACTURE AND APPLICATIONS |
| CA2766861A1 (en) * | 2009-07-09 | 2011-01-13 | F. Hoffmann-La Roche Ag | In vivo tumor vasculature imaging |
| KR102040476B1 (ko) * | 2012-03-26 | 2019-11-06 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 촬상 및 치료를 위한 에틸렌디시스테인-당 콘쥬게이트의 효율적 합성법 |
| KR102124442B1 (ko) * | 2018-09-11 | 2020-06-23 | 서울대학교산학협력단 | 황화수소 검출 또는 농도 측정용 조성물 및 이를 유효성분으로 함유하는 생체내 염증, 저산소 손상조직 또는 암의 진단 또는 영상화용 조성물 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US4507466A (en) * | 1983-01-07 | 1985-03-26 | The Dow Chemical Corporation | Dense star polymers having core, core branches, terminal groups |
| US4568737A (en) * | 1983-01-07 | 1986-02-04 | The Dow Chemical Company | Dense star polymers and dendrimers |
| US4558120A (en) * | 1983-01-07 | 1985-12-10 | The Dow Chemical Company | Dense star polymer |
| US4737550A (en) * | 1983-01-07 | 1988-04-12 | The Dow Chemical Company | Bridged dense star polymers |
| US4631337A (en) * | 1983-01-07 | 1986-12-23 | The Dow Chemical Company | Hydrolytically-stable dense star polyamine |
| US4587329A (en) * | 1984-08-17 | 1986-05-06 | The Dow Chemical Company | Dense star polymers having two dimensional molecular diameter |
| US4732863A (en) * | 1984-12-31 | 1988-03-22 | University Of New Mexico | PEG-modified antibody with reduced affinity for cell surface Fc receptors |
| US4871779A (en) * | 1985-12-23 | 1989-10-03 | The Dow Chemical Company | Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities |
| US4694064A (en) * | 1986-02-28 | 1987-09-15 | The Dow Chemical Company | Rod-shaped dendrimer |
| US4861869A (en) * | 1986-05-29 | 1989-08-29 | Mallinckrodt, Inc. | Coupling agents for joining radionuclide metal ions with biologically useful proteins |
| US4713975A (en) * | 1986-05-30 | 1987-12-22 | The Dow Chemical Company | Dense star polymers for calibrating/characterizing sub-micron apertures |
| IN165717B (zh) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5279811A (en) * | 1987-02-18 | 1994-01-18 | The Du Pont Merck Pharmaceutical Company | Ester-substituted diaminedithiols and radiolabeled complexes thereof |
| US4965392A (en) * | 1987-03-26 | 1990-10-23 | Neorx Corporation | Chelating compounds for metal-radionuclide labeled proteins |
| US4857599A (en) * | 1988-02-08 | 1989-08-15 | The Dow Chemical Company | Modified dense star polymers |
| US5164294A (en) * | 1988-05-17 | 1992-11-17 | Syntex (U.S.A.) Inc. | Method for immunochromatographic analysis |
| US4988496A (en) * | 1988-05-31 | 1991-01-29 | Neorx Corporation | Metal radionuclide chelating compounds for improved chelation kinetics |
| US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5688488A (en) * | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
| JP2517760B2 (ja) * | 1989-05-11 | 1996-07-24 | 新技術事業団 | 水溶性高分子化医薬製剤 |
| CA2080685A1 (en) | 1990-04-17 | 1991-10-18 | Alfons Verbruggen | Method and kit for preparing technetium-99m complexes |
| US5385719A (en) * | 1991-09-24 | 1995-01-31 | Unger; Evan C. | Copolymers and their use as contrast agents in magnetic resonance imaging and in other applications |
| US6113946A (en) * | 1992-04-03 | 2000-09-05 | The Regents Of The University Of California | Self-assembling polynucleotide delivery system comprising dendrimer polycations |
| US5605671A (en) * | 1992-10-05 | 1997-02-25 | The Regents Of The University Of Michigan | Radiolabeled neutrophil activating peptides for imaging |
| US5951964A (en) * | 1993-06-04 | 1999-09-14 | Diatide, Inc. | Technetium-99m labeled peptides for imaging |
| US5605672A (en) | 1993-06-09 | 1997-02-25 | The General Hospital Corporation | Blood pool imaging composition and method of its use |
| US5534241A (en) * | 1993-07-23 | 1996-07-09 | Torchilin; Vladimir P. | Amphipathic polychelating compounds and methods of use |
| US5443953A (en) * | 1993-12-08 | 1995-08-22 | Immunomedics, Inc. | Preparation and use of immunoconjugates |
| US5730968A (en) * | 1994-03-31 | 1998-03-24 | Sterling Winthrop Inc. | Segmented chelating polymers as imaging and therapeutic agents |
| US5670132A (en) * | 1994-09-20 | 1997-09-23 | Immunomedics, Inc. | Modified radioantibody fragments for reduced renal uptake |
| WO1996015811A1 (en) * | 1994-11-17 | 1996-05-30 | Imperial College Of Science, Technology & Medicine | Internalisation of dna, using conjugates of poly-l-lysine and an integrin receptor ligand |
| US5830431A (en) * | 1995-06-07 | 1998-11-03 | Mallinckrodt Medical, Inc. | Radiolabeled peptide compositions for site-specific targeting |
| US5908777A (en) * | 1995-06-23 | 1999-06-01 | University Of Pittsburgh | Lipidic vector for nucleic acid delivery |
| US5808146A (en) | 1995-11-09 | 1998-09-15 | Emory University | Amino acid analogs for tumor imaging |
| KR100561788B1 (ko) * | 1996-03-12 | 2006-09-20 | 피지-티엑스엘 컴파니,엘.피. | 수용성파클리탁셀전구약물을포함하는조성물및이러한조성물을포함하는이식가능한의료장치 |
| US6441025B2 (en) * | 1996-03-12 | 2002-08-27 | Pg-Txl Company, L.P. | Water soluble paclitaxel derivatives |
| US5986074A (en) | 1996-05-06 | 1999-11-16 | Emory University | Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof |
| US5955053A (en) | 1996-05-06 | 1999-09-21 | Emory University | Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof |
| ES2392246T3 (es) * | 1996-11-12 | 2012-12-07 | The Regents Of The University Of California | Preparación de formulaciones estables de complejos de lípido-ácido nucleico para el suministro eficaz in vivo |
| ES2398118T3 (es) * | 1997-04-30 | 2013-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Procedimiento de formación de imágenes de muerte celular in vivo |
| US6251866B1 (en) * | 1997-08-05 | 2001-06-26 | Watson Laboratories, Inc. | Conjugates targeted to the interleukin-2 receptor |
| US20010041189A1 (en) * | 1999-04-13 | 2001-11-15 | Jingya Xu | Poly(dipeptide) as a drug carrier |
| US6284220B1 (en) | 1999-06-03 | 2001-09-04 | The General Hospital Corporation | Noninvasive imaging of nucleic acid vectors |
| CN1315554A (zh) | 2000-03-24 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人atp依赖的丝氨酸蛋白水解酶31和编码这种多肽的多核苷酸 |
| WO2001080906A2 (en) | 2000-04-20 | 2001-11-01 | The University Of British Columbia | Radiometal complexes of 2-pyrrolylthiones for imaging a therapy |
| BRPI0111220B8 (pt) * | 2000-06-02 | 2021-07-27 | Univ Texas | conjugados de fármacos com etilenodicisteína (ec) |
| CA2425873A1 (en) | 2000-10-19 | 2002-04-25 | The General Hospital Corporation | Imaging of enzymatic activity |
-
2003
- 2003-11-07 CA CA002505537A patent/CA2505537A1/en not_active Abandoned
- 2003-11-07 BR BR0316046-7A patent/BR0316046A/pt not_active IP Right Cessation
- 2003-11-07 KR KR1020057008175A patent/KR101086690B1/ko active IP Right Grant
- 2003-11-07 AU AU2003297261A patent/AU2003297261B2/en not_active Expired
- 2003-11-07 US US10/703,405 patent/US20040166058A1/en not_active Abandoned
- 2003-11-07 CN CN201010295764XA patent/CN101985443A/zh active Pending
- 2003-11-07 JP JP2004552132A patent/JP2006515835A/ja active Pending
- 2003-11-07 WO PCT/US2003/036078 patent/WO2004044227A2/en active Application Filing
- 2003-11-07 PL PL377107A patent/PL377107A1/pl not_active Application Discontinuation
- 2003-11-07 EP EP03811262A patent/EP1562641A4/en not_active Withdrawn
- 2003-11-07 EP EP11155333A patent/EP2316493A3/en not_active Withdrawn
- 2003-11-07 CN CN2003801053186A patent/CN1723042B/zh not_active Expired - Lifetime
-
2005
- 2005-05-03 IL IL168376A patent/IL168376A/en active IP Right Grant
- 2005-05-10 NO NO20052265A patent/NO20052265L/no not_active Application Discontinuation
-
2009
- 2009-01-20 AU AU2009200201A patent/AU2009200201B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| IL168376A (en) | 2011-06-30 |
| KR20050088289A (ko) | 2005-09-05 |
| PL377107A1 (pl) | 2006-01-23 |
| CA2505537A1 (en) | 2004-05-27 |
| KR101086690B1 (ko) | 2011-11-25 |
| AU2003297261B2 (en) | 2008-10-23 |
| CN1723042A (zh) | 2006-01-18 |
| NO20052265D0 (no) | 2005-05-10 |
| WO2004044227A3 (en) | 2004-11-11 |
| AU2009200201B2 (en) | 2010-06-24 |
| EP2316493A3 (en) | 2011-08-10 |
| BR0316046A (pt) | 2005-09-13 |
| EP1562641A4 (en) | 2008-12-03 |
| AU2009200201A1 (en) | 2009-02-12 |
| AU2003297261A1 (en) | 2004-06-03 |
| JP2006515835A (ja) | 2006-06-08 |
| CN101985443A (zh) | 2011-03-16 |
| US20040166058A1 (en) | 2004-08-26 |
| WO2004044227A2 (en) | 2004-05-27 |
| EP2316493A2 (en) | 2011-05-04 |
| EP1562641A2 (en) | 2005-08-17 |
| CN1723042B (zh) | 2010-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20052265L (no) | Etylendicystein (EC)-medikament konjugater og fremgangsmater for vevsspesifik sykdomsbilleddannelse | |
| WO2009073546A3 (en) | Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7) | |
| MA29595B1 (fr) | Anticorps anti-cd40 humanises et procedes d'utilisation | |
| NO20063539L (no) | Anti-glypican 3 antistoff | |
| EA200801461A1 (ru) | Агенты, связывающиеся с ядерными рецепторами | |
| MY188455A (en) | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates | |
| HK1217103A1 (zh) | 二芳基乙內酰脲化合物 | |
| WO2008141044A3 (en) | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates | |
| WO2006096491A3 (en) | Anti-ctla-4 antibody compositions | |
| WO2006034488A3 (en) | Cysteine engineered antibodies and conjugates | |
| ATE516842T1 (de) | Intravasculärer führungsdraht | |
| WO2003100033A3 (en) | ANTI-αvβ6 ANTIBODIES | |
| WO2006113432A3 (en) | Compounds, compositions and methods | |
| WO2008053330A3 (en) | Monoclonal antibodies against the human anti-mullerian hormone type ii receptor (amhr-ii) | |
| WO2006110745A3 (en) | Conjugated anti-psma antibodies | |
| TW200630381A (en) | Tumor endothelial marker-1 (TEM1) binding antibodies and uses thereof | |
| ATE427174T1 (de) | Syntheseverfahren fur metallnanopartikel | |
| WO2007019541A3 (en) | Antibody compositions, methods for treating neoplastic disease and methods for regulating fertility | |
| WO2006029220A3 (en) | Combination therapy with anti-ctla4 and anti-4-1bb antibodies | |
| DK1794302T3 (da) | Fremgangsmåde til at forøge frøvægt | |
| NZ552372A (en) | Propane-1,3-dione derivative or its salt | |
| Kraus et al. | A three-component reaction between benzynes, the enolate of acetaldehyde, and unsaturated esters and dihydroisoquinolines | |
| ATE451393T1 (de) | Humane anti-idiotypische antikörperfragmente, die her-2/neu ähneln | |
| WO2007002126A8 (en) | Alkyl sulfonamide derivatives | |
| BG108932A (en) | Pharmaceutical composition comprising arsenite for the treatment of malignancy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |